Laetitia Rouxel

CFO

Equibles does not estimate personal net worth.

Get an email with a short summary when Evotec SE publishes a filing, an earnings call transcript or a press release.

About Laetitia Rouxel

Laetitia Rouxel is recorded as CFO at Evotec SE (EVO). Laetitia Rouxel has spoken on 5 earnings calls across 1 company, most recently for Evotec SE on September 30, 2024. Evotec SE is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.

Laetitia Rouxel on recent calls

“Let me now guide you through our nine-month financial results in more detail. Nine months group revenues have reached €575.7 million in line with the same period in 2023, and this is driven by two counterbalanced trends.”

CFO, Evotec SE Q3 FY2024 Earnings Call · September 30, 2024

“Let me now guide you through our H1 financial results in more detail. In H1 '24, we achieved EUR390.8 million revenue, which represents a slight 2% increase compared to the same period in 2023.”

CFO, Evotec SE Q2 FY2024 Earnings Call · June 30, 2024

“In Q1 2024, we achieved €208.8 million in revenue, which represents a slight 2% decrease compared to the same period in 2023.”

CFO, Evotec SE Q1 FY2024 Earnings Call · March 31, 2024

“Thank you, Werner, and welcome everyone for joining us today to discuss our financial performance over the past nine months. As shown in slide eight, we had a very strong start to the year with revenues in Q1 2023 reaching €213.6 million, representing a growth of 30% compared to Q1 2022.”

CFO, Evotec SE Q3 FY2023 Earnings Call · September 30, 2023

“It's my pleasure to walk you through half-year financials and the guidance for 2023, which we, as you all know, updated on 27th of July. We had a very strong start to the year, with revenues in Q1 at €213.6 million, which implies a growth of 30% versus Q1 of the prior year.”

CFO, Evotec SE Q2 FY2023 Earnings Call · June 30, 2023